1. Strategic Cooperation Achievements
Signed a Customized Chiral Intermediate Agreement with Germany's Merck Group: Supplied enantiopure (R)-phenylglycinol and (S)-lactic acid derivatives for Merck's cardiovascular drug production, with an annual supply volume of 3,800 tons and a contract value of 28 million US dollars. The products feature enantiomeric excess (ee) ≥ 99.5% and impurity content 1%, becoming Merck's core alternative to Japanese suppliers for this product category.
Participated in Thailand's Pharmaceutical Park Project: Provided key intermediates (including piperazine derivatives and imidazole compounds) for Thailand's National Pharmaceutical Manufacturing Center, and exported green synthesis technology. The project has a contract value of 180 million US dollars with an annual supply volume of 1,800 tons, supporting Thailand's local production of anti-diabetic and anti-hypertensive drugs.
2. Export Scale Cases
Explosive Export Growth in the RCEP Region: Taking advantage of RCEP's tariff reduction on pharmaceutical products (average tariff reduction from 8% to 0.5%), exported benzene series intermediates, heterocyclic compounds and other products to Australia, New Zealand and 8 ASEAN countries, with an annual export volume of 18,000 tons and an export value of 320 million RMB, a year-on-year increase of 65%. Among them, export growth to Malaysia and the Philippines exceeded 75%.
Export of High-purity API Intermediates to South America: For the first time exported cefazolin sodium intermediates and amoxicillin side chains to Brazil and Argentina, with an annual export volume of 3,000 tons and an export value of 47 million RMB. It has become a preferred import substitution brand in South America's API production industry, with market share increasing from 0 to 6%.
3. Market Breakthrough Cases
Leading Quinolone Intermediates in Southeast Asia: Developed norfloxacin intermediates (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1-yl-3-quinolinecarboxylic acid) tailored to the region's anti-infective drug demand, capturing 20% of the market in Vietnam and Indonesia with annual sales of 98 million RMB, a year-on-year growth of 90%. Cooperation clients include Daiichi Sankyo Vietnam and Kalbe Farma Indonesia.
RCEP Cross-border Pharmaceutical Logistics Optimization: Launched a dedicated cold-chain logistics route via Guangxi-Beibu Gulf Port to Southeast Asia, transporting temperature-sensitive intermediates (such as peptide intermediates) with an annual shipment volume of 10,000 tons, a 105% increase compared with 2022. Logistics costs were reduced by 18% and on-time delivery rate reached 99%.
Jun 13, 26
Analyzing Oxandrolone Side Effects and Selective Peptides
Understanding the nuances of pharmaceutical interactions and potential oxandrolone side effects is critical for researchers and clinicians aiming to optimize patient outcomes in metabolic and cardiovascular studies. While many chemical compounds offer profound therapeutic potential, the ability to distinguish between intended biological activity and adverse reactions ensures a higher standard of safety and efficacy in translational medicine. On a global scale, the demand for high-purity research peptides and active pharmaceutical ingredients has surged as scientific communities seek to mitigate the risks associated with legacy treatments.
Jun 12, 26
Clinical Guide to Oxandrolone Uses and Metabolic Benefits
In the contemporary landscape of metabolic medicine and pharmaceutical research, understanding the diverse oxandrolone uses is pivotal for clinicians and researchers alike. While the industry continues to evolve, the demand for high-purity active pharmaceutical ingredients APIs remains the cornerstone of effective therapeutic outcomes, particularly in treating muscle wasting and metabolic dysfunction. The global shift toward personalized medicine has highlighted the importance of specific androgenic agents and GLP-1 agonists in managing complex patient profiles. By analyzing the systemic impact of these compounds, the pharmaceutical sector can better address the needs of patients recovering from severe trauma or managing chronic endocrine imbalances.
Jun 11, 26
Salmon Calcitonin and oxandrolone use for Bone Health
The global pharmaceutical landscape is increasingly focusing on the precision of bone metabolism regulation, where the strategic oxandrolone use is often discussed in the context of anabolic recovery, yet the specialized application of Salmon Calcitonin provides a critical alternative for systemic calcium management. Understanding the nuanced differences between anabolic agents and calcitonin-based therapies is essential for healthcare providers aiming to treat severe osteoporosis and hypercalcemia. In the realm of chemical raw material manufacturing, the production of high-purity peptides like Salmon Calcitonin represents a pinnacle of biotechnological achievement. While some research focuses on oxandrolone use for muscle wasting, Salmon Calcitonin targets the osteoclast directly,
Contact Us
Professional Chemical Supply, Efficient Service
Subscribe For Newsletter!
Your Email...
